EUVIMEDEUVIMED entdecken
Crossref

Comparative Evaluation of the Efficacy of Antithymocyte Globulin versus Basiliximab in Preventing Rejection PostRenal Transplantation

Lubina Sahnas, Shirin K, Dr. Shamnas M

International Journal of Drug Delivery Technology · 24.04.2026 · 16 (18s)

DOI: 10.25258/ijddt.16.18s.63 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Drug Delivery Technology, online erschienen am 24.04.2026. Verfasst von Lubina Sahnas und 2 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Renal transplantation remains the preferred treatment for end-stage renal disease (ESRD), but graft rejection remains a significant concern. The use of induction immunosuppressive agents such as Antithymocyte Globulin (ATG) and Basiliximab (BSX) has improved graft outcomes; however, comparative data regarding their efficacy profiles in Indian population is limited. This was a prospective, observational study conducted to compare the efficacy of Thymoglobulin versus Basiliximab in preventing acute graft rejection among renal transplant recipients at Govt. Medical College, Kozhikode. Patients receiving either ATG or BSX induction therapy were followed for 6 months post renal transplantation. Clinical and biochemical parameters such as hemoglobin, WBC, platelet count, BUN, serum creatinine and creatinine clearance were assessed. Statistical analyses were performed using IBM SPSS v25. Baseline demographic and clinical parameters were comparable between the groups. Both induction regimens significantly improved renal function markers — blood urea nitrogen, serum creatinine, and creatinine clearance — at Week 3 and Month 3 post-transplant (p < 0.001), with no significant intergroup difference, indicating comparable efficacy in early graft function recovery. Hematological analysis revealed significant post-transplant anemia in both groups, while WBC suppression was more pronounced with Thymoglobulin, consistent with its lymphocyte-depleting effect. Platelet counts showed transient elevation in both groups. Electrolyte trends included mild hyponatremia and hyperkalemia with Thymoglobulin and more pronounced hypophosphatemia with Basiliximab. Both ATG and BSX are effective as induction agents in renal transplantation, but ATG offers slightly better protection against early rejection, albeit with higher adverse event rates. Individualization of induction therapy based on immunologic risk and comorbidity profile is recommended.

Zitieren

APA

Sahnas, L., K, S., & M, D. S. (2026). Comparative Evaluation of the Efficacy of Antithymocyte Globulin versus Basiliximab in Preventing Rejection PostRenal Transplantation. International Journal of Drug Delivery Technology, 16(18s). https://doi.org/10.25258/ijddt.16.18s.63

Vancouver

Sahnas L, K S, M DS. Comparative Evaluation of the Efficacy of Antithymocyte Globulin versus Basiliximab in Preventing Rejection PostRenal Transplantation. International Journal of Drug Delivery Technology. 2026;16(18s). doi:10.25258/ijddt.16.18s.63

BibTeX
@article{Sahnas2026,
  author = {Sahnas, Lubina and K, Shirin and M, Dr. Shamnas},
  title = {Comparative Evaluation of the Efficacy of Antithymocyte Globulin versus Basiliximab in Preventing Rejection PostRenal Transplantation},
  journal = {International Journal of Drug Delivery Technology},
  year = {2026},
  volume = {16},
  number = {18s},
  doi = {10.25258/ijddt.16.18s.63}
}
Kostenlos starten →